neurology
MIDAS — Migraine Disability Assessment
Migraine Disability Assessment questionnaire measures days of disability from migraines in the past 3 months across work, household, and social domains. Guides treatment intensity.
References
- Stewart WF et al. Development and testing of the Migraine Disability Assessment (MIDAS) questionnaire to assess headache-related disability. Neurology. 2001;56(6 Suppl 1):S20–28.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Erenumab · CGRP Receptor Monoclonal Antibody — Migraine Prevention
- Propranolol (Migraine Prevention) · Beta-Blocker — Migraine Prophylaxis
- Atogepant · CGRP Receptor Antagonist (Gepant — Migraine Prevention)
- Thiamine (IV/IM — Pabrinex) · Vitamin B1 (Thiamine) — deficiency treatment / Wernicke's encephalopathy prevention
- Anthrax Vaccine · Vaccine (Bacterial — Anthrax Prevention)
- Edoxaban (AF Stroke Prevention / VTE) · Direct Factor Xa Inhibitor (DOAC)
Pathways
- Acute Stroke / TIA Assessment · NICE NG128; RCP Stroke Guidelines 2023
- Status Epilepticus (Adults) · NICE CG137; ESEM guidelines; RCP Neurology Guidelines
- Acute Stroke Management · NICE NG128 / RCP 2023
- TIA Assessment (ABCD2) · NICE NG128 / NICE CG68
- Bacterial Meningitis (Adults) · NICE CG102 / BIA 2016
- Parkinson's Disease Management · NICE NG71 2017
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.